Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B1IP
|
|||
| Former ID |
DIB004385
|
|||
| Drug Name |
Etretinate
|
|||
| Synonyms |
etretinate; 54350-48-0; Tegison; Ethyl etrinoate; Retinoid; Etretinatum; Etretinato; Ro 10-9359; Etretinatum [INN-Latin]; Etretinato [INN-Spanish]; UNII-65M2UDR9AG; CCRIS 3615; HSDB 7185; EINECS 259-119-3; NSC 297936; 65M2UDR9AG; Ro-10-9359; Tigason; CHEBI:4913; C23H30O3; Ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; Ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; 3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonanetetraenoic acid ethy
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Keratosis [ICD-11: ED56; ICD-10: L57.0] | Approved | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H30O3
|
|||
| Canonical SMILES |
CCOC(=O)C=C(C)C=CC=C(C)C=CC1=C(C(=C(C=C1C)OC)C)C
|
|||
| InChI |
1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+
|
|||
| InChIKey |
HQMNCQVAMBCHCO-DJRRULDNSA-N
|
|||
| CAS Number |
CAS 54350-48-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
147405, 7847382, 7979209, 8617028, 12013448, 14754444, 24702109, 39315832, 48415995, 49997871, 50112753, 50140619, 56352872, 57358640, 71821675, 92309122, 92716748, 92729647, 93304521, 103167534, 103825409, 113857080, 117577847, 126622714, 126663123, 127324001, 127324002, 131318257, 135002908, 137005793, 137128958, 138097872, 139221756, 144206054, 152029411, 162173068, 164827405, 170465372, 175611923, 176262082, 176484353, 177749313, 179116679, 179225741, 184546000, 198959792, 198992373, 223365934, 223673365, 225039591
|
|||
| ChEBI ID |
CHEBI:4913
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Etretinate (adjusted p-values: 3.41E-04). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7599). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.